SG Americas Securities
ICPT

SG Americas Securities’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

SG Americas Securities’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,000
Closed -$94K – 3520
2019
Q1 		$94K Buy
+20,000
New +$2.19M ﹤0.01% 3082

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SG Americas Securities's ICPT Position: Q4 2022 in Review

SG Americas Securities sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 202,239 shares — an estimated $2.82M sold.

SG Americas Securities first reported a position in ICPT in Q3 2013 and held it in 33 quarters. The position peaked at $3.4M in Q3 2015. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • SG Americas Securities reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • SG Americas Securities sold 202,239 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $2.82M.
  • SG Americas Securities first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 33 quarters.
  • SG Americas Securities's Intercept Pharmaceuticals, Inc. position peaked at $3.4M in Q3 2015.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on SG Americas Securities's 13F filing for Q4 2022, filed 2 Feb 2023.